Otorhinolaryngology Department, Vakif Gureba Training and Research Hospital, Vatan Street, Fatih, Istanbul, Turkey.
Eur Arch Otorhinolaryngol. 2010 Sep;267(9):1377-81. doi: 10.1007/s00405-010-1208-0. Epub 2010 Feb 13.
This is a study evaluating the efficacy of Ankaferd Blood Stopper (ABS) as a hemostatic agent compared to hemostasis by phenylephrine in patients with anterior epistaxis. The study design is a prospective, randomized, controlled, nonblinded, clinical trial. In total, 49 patients were randomly seperated to receive hemostasis technique by means of either ABS wet tampon or phenylephrine impregnated gauze tampon for anterior epistaxis control. Patients were crossed over to the other technique after two unsuccessful attempts of the first technique. Measured outcomes such as number of applications, relationship of number of applications with bleeding intensity (1 = stains on napkin, 2 = soaked napkin, 3 = bowl needed), patient discomfort during hemostasis (0 = none, 9 = unbearable), and complications were assessed. Additional data were recorded for rebleeding within 7 days. 24 of the 49 patients were assigned to the new ABS group (group I) and remaining 25 were included in the standard phenylephrine group (group II). ABS was more effective than phenylephrine at control of anterior epistaxis (79.2 vs. 64%, p < 0.05). For the patients who crossed over from phenylephrine to ABS, 44.4% achieved hemostasis by ABS. ABS successfully treated all bleeding intensity 1 and 2 patients with one application (5 min). ABS patients experienced fewer rebleeding rates within 7 days compared to phenylephrine patients (8.3 vs. 20%, p < 0.05). The patients for which ABS was applied, significant differences in effective control of anterior epistaxis were observed compared to phenylephrine. ABS is effective, safe, quick, and easy alternative to the phenylephrine in patients with anterior epistaxis.
这是一项评估 Ankaferd Blood Stopper（ABS）作为止血剂与苯肾上腺素在治疗前鼻出血患者中的疗效的研究。该研究设计为前瞻性、随机、对照、非盲、临床试验。共 49 例患者随机分为接受 ABS 湿棉条或苯肾上腺素浸渍纱布棉条止血技术用于前鼻出血控制的两组。如果首次尝试两种技术均不成功，患者将交叉至另一组。评估的测量结果包括应用次数、应用次数与出血强度的关系（1 = 餐巾上有血迹，2 = 餐巾浸湿，3 = 需要碗）、止血过程中患者的不适（0 = 无，9 = 无法忍受）和并发症。还记录了 7 天内再次出血的额外数据。49 例患者中的 24 例被分配到新的 ABS 组（I 组），其余 25 例被纳入标准苯肾上腺素组（II 组）。ABS 在前鼻出血控制方面比苯肾上腺素更有效（79.2% vs. 64%，p < 0.05）。从苯肾上腺素交叉到 ABS 的患者中，44.4%的患者通过 ABS 达到止血。ABS 成功地用一次应用（5 分钟）治疗了所有出血强度为 1 和 2 的患者。与苯肾上腺素组相比，ABS 组患者在 7 天内再次出血的发生率较低（8.3% vs. 20%，p < 0.05）。与苯肾上腺素相比，应用 ABS 的患者在前鼻出血的有效控制方面存在显著差异。ABS 是治疗前鼻出血患者的一种有效、安全、快速、简便的苯肾上腺素替代方法。
